Wang Zhiliang, Morelli Adrian E, Hackstein Holger, Kaneko Katsuhiko, Thomson Angus W
Thomas E Starzl Transplantation Institute and Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
Transplantation. 2003 Aug 15;76(3):562-71. doi: 10.1097/01.TP.0000068901.11693.C3.
Combination of donor dendritic cells (DC) and anti-CD40 Ligand (L) (CD154) monoclonal antibody (mAb) markedly prolongs heart or skin allograft survival, but the influence of this strategy in models of chronic rejection is unknown. Our aim was to ascertain the influence of in vivo-mobilized immature donor DC plus anti-CD40L mAb on vascular sclerosis in functional murine aortic allografts.
C3H He/J (C3H;H2k) mice received 2 x 106 freshly isolated, immunobead-purified (>90%) fms-like tyrosine kinase 3 ligand-mobilized C57BL/10 (B10;H2b) CD11c+ DC intravenously (IV), together with 500 microg of anti-CD40L mAb (MR1) intraperitoneally (IP) on days -7, 0, 4, and 10. Controls received either no donor cells, no mAb, or were untreated. B10 aortic grafts were transplanted in the abdominal aorta on day 0. At day 30, antidonor T-cell proliferative and cytotoxic responses and both complement fixing and immunoglobulin (Ig)G alloantibody levels were determined. Grafts were harvested on days 30 and 60 and examined by histology and immunohistochemistry.
DC infusion alone enhanced ex vivo antidonor proliferative and cytotoxic T-cell activity. By contrast, complement-fixing alloantibody levels were reduced. Anti-CD40L mAb alone strongly suppressed each of these responses. Graft inflammatory cell infiltration, intimal smooth muscle cell proliferation, fibrosis, and elastic lamina disruption observed in untreated animals were reduced in response to anti-CD40L mAb or donor DC alone. Antidonor immune reactivity, including IgG levels, and intimal proliferation were all markedly suppressed to an overall greater extent in mice given both treatments.
Whereas blockade of the CD40-CD40L pathway ameliorated transplant vasculopathy, preservation of near-normal vessel architecture was achieved by simultaneous administration of donor DC. This strategy represents a novel application of DC for suppression of chronic rejection.
供体树突状细胞(DC)与抗CD40配体(L)(CD154)单克隆抗体(mAb)联合应用可显著延长心脏或皮肤同种异体移植物的存活时间,但该策略在慢性排斥反应模型中的影响尚不清楚。我们的目的是确定体内动员的未成熟供体DC加抗CD40L mAb对功能性小鼠主动脉同种异体移植物血管硬化的影响。
C3H He/J(C3H;H2k)小鼠在第-7、0、4和10天静脉内(IV)接受2×10⁶新鲜分离、免疫磁珠纯化(>90%)的fms样酪氨酸激酶3配体动员的C57BL/10(B10;H2b)CD11c⁺ DC,同时腹腔内(IP)注射500μg抗CD40L mAb(MR1)。对照组不接受供体细胞、不接受mAb或不进行处理。在第0天,将B10主动脉移植物移植到腹主动脉中。在第30天,测定抗供体T细胞增殖和细胞毒性反应以及补体固定和免疫球蛋白(Ig)G同种异体抗体水平。在第30天和60天收获移植物,通过组织学和免疫组织化学进行检查。
单独输注DC可增强体外抗供体增殖和细胞毒性T细胞活性。相比之下,补体固定同种异体抗体水平降低。单独使用抗CD40L mAb可强烈抑制这些反应中的每一种。在未处理的动物中观察到的移植物炎性细胞浸润、内膜平滑肌细胞增殖、纤维化和弹性层破坏,对抗CD40L mAb或单独的供体DC有反应性降低。在接受两种治疗的小鼠中,包括IgG水平在内的抗供体免疫反应性和内膜增殖均受到更明显的总体抑制。
虽然阻断CD40 - CD40L途径可改善移植血管病,但通过同时给予供体DC可实现接近正常血管结构的保留。该策略代表了DC在抑制慢性排斥反应中的一种新应用。